                               SEQUENCE LISTING

<110> SERIMMUNE INC.
 
<120> IMMUNOME WIDE ASSOCIATION STUDIES TO IDENTIFY CONDITION-SPECIFIC 
      ANTIGENS

<130> SUI-005WO

<140> PCT/US2020/038856
<141> 2020-06-20

<150> 62/864,909
<151> 2019-06-21

<160> 3     

<170> PatentIn version 3.5

<210> 1
<211> 53
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer


<220>
<221> modified_base
<222> (34)..(38)
<223> a, c, t, g, unknown or other

<400> 1
tcgtcggcag cgtcagatgt gtataagaga cagnnnnncc agtctggcca ggg              53


<210> 2
<211> 54
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 2
ccagtactac ggcatcactg ctgtctctta tacacatctc cgagcccacg agac             54


<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (3)..(4)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (7)..(7)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Glu or Asp

<400> 3
Gln Pro Xaa Xaa Pro Phe Xaa Xaa 
1               5               


